Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GILDBullishIndustry Newsnews

High materiality7/10

Gilead's Livdelzi IDEAL data expand ALP normalization in PBC with regulatory path ahead

Jun 2, 2026, 2:07 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3 efficacy signals for a liver-disease asset can reframe risk/reward, despite short-term price weakness, by expanding addressable population and regulatory visibility.

AI summary

What happened, with direct paths to the underlying reporting

Gilead reported IDEAL Phase 3 results for seladelpar (Livdelzi) in primary biliary cholangitis, showing superior ALP normalization after 52 weeks in inadequately controlled patients. The company will present full data at a medical congress and plans regulatory discussions, potentially expanding Livdelzi's use if approvals follow.

IDEAL 3 shows seladelpar improves ALP normalization vs placebo at 52 weeks in PBC.
Population: inadequately controlled PBC with UDCA intolerance; ALP normalization pursued.
No new safety concerns; Livdelzi safety profile aligns with prior studies.
Data to be presented at medical congress; regulatory discussions planned.
ASSURE Phase 3: 83% normalization at 12 months, 74% at 24 months in 50 participants.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Gilead's Livdelzi IDEAL data expand ALP normalization in PBC with regulatory path ahead

Gilead Wins Court Ruling Restricting Overseas Drug Import AFPs

California Court Rules in Gilead Favor on Safer-Drug Development Obligation

Gilead and Merck weekly HIV regimen shows viral suppression, filings expected

HSBC Upgrade to Buy Signals Early GILD Upside on HIV/Oncology Catalysts